← Back to Search

Gas

Hyperpolarized Xe129 for Coronavirus

Phase 1

Waitlist Available

Research Sponsored by University of Kansas Medical Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 6-months

Awards & highlights

Study Summary

This trial will help researchers understand how different levels of COVID-19 severity affect pulmonary function and how quickly patients recover.

Who is the study for?

This trial is for people who had COVID-19 and are in outpatient follow-up. They must be at least 10 days past the start of symptoms, without a fever, able to understand English or Spanish, and have an oxygen saturation of ≥88%. Pregnant individuals, those unable to fit into the MRI vest or hold their breath for about 15 seconds, under 18 years old, or with certain cognitive deficits cannot participate.Check my eligibility

What is being tested?

The study is testing hyperpolarized Xe129 MRI's ability to assess lung function in patients who've recovered from mild to severe COVID-19. It aims to provide insights on how well their lungs are working post-infection using this advanced imaging technique.See study design

What are the potential side effects?

There may not be direct side effects from the hyperpolarized Xe129 itself; however, undergoing an MRI might cause discomfort due to having to remain still for a period of time and noise during the procedure. There's also a small risk associated with inhaling xenon gas used in this type of imaging.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 6-months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~6-months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 6-months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Ventilation Defect Percentage

Trial Design

1Treatment groups

Experimental Treatment

Group I: COVID-19 SurvivorsExperimental Treatment1 Intervention

Subjects recovering from COVID-19 disease will be imaged using hyperpolarized 129Xe MRI.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of Kansas Medical CenterLead Sponsor

465 Previous Clinical Trials

169,214 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What additional investigations have explored the effects of Hyperpolarized Xe129?

"There are currently 15 Hyperpolarized Xe129 trials in progress, none of which are at their final stage. The majority of these experiments take place in Philadelphia but span across 21 medical locations."

Answered by AI

Are healthcare professionals authorized to use Hyperpolarized Xe129 in treatment?

"Due to the limited amount of research data available, Hyperpolarized Xe129 has been given a safety rating of 1. As this is a Phase 1 trial, there is minimal evidence for efficacy and safety at present."

Answered by AI

Are there any open slots left for participants in this research?

"Verified. Information hosted on clinicaltrials.gov confirms that this research endeavour, which was originally launched on February 22nd 2021, is currently recruiting individuals for participation. 20 persons need to be recruited from 1 medical centre."

Answered by AI

How many participants are engaged in this trial?

"Affirmative. The records on clinicaltrials.gov verify that recruitment for this medical trial is still active since it was created in February 2021 and recently updated in August 2022. Currently, the research team needs to acquire 20 participants from a single facility."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Hyperpolarized 129Xe MRI of Survivors of COVID-19

Peter J. Niedbalski, PhD 2021. "Hyperpolarized 129Xe MRI of Survivors of COVID-19". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04659707.

All > Coronavirus